ClinicalTrials.gg
CompletedNCT05428436Updated Dec 19, 2025Results posted

A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food

A Phase 1 interventional study of Reference (R) and Test treatment 1 (T1) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main objective of this trial is to investigate the relative bioavailability of BI 1015550 intended Commercial Formulation (iCF) compared with Trial Formulation 2 (TF2) and the effect of food on the pharmacokinetics of BI 1015550 iCF following oral administration.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests.
  • Age of 18 to 55 years (inclusive).
  • (BMI) of 18.5 to 29.9 kg/m2 (inclusive).
  • Signed and dated written in accordance with International Council for Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
  • Either male subject, or female subject who meet any of the following criteria from 30 days before drug administration until 7 days after trial completion:

    • Use of non-oral hormonal associated with inhibition of ovulation:

intravaginal or transdermal combinations of estrogen and progestogen or injectable or implantable progestogen.

  • Use of intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).
  • Sexually abstinent, i.e. complete abstinence from male-female sex when this is in line with the preferred and usual lifestyle of the study participant. Periodic abstinence e.g. calendar, ovulation, symptothermal, post-ovulation methods; declaration of abstinence for the duration of exposure to study drug; and withdrawal are not acceptable.
  • Vasectomised sexual partner with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate, provided that partner is the sole sexual partner of the study participant
  • Surgically sterilised (including hysterectomy, bilateral salpingectomy, bilateral oophorectomy, bilateral tubal occlusion).
  • , defined as no menses for 1 year without an alternative medical cause (in questionable cases a blood sample with levels of follicle stimulating hormone (FSH) above 40 U/L and estradiol below 30 ng/L is confirmatory).

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator-
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm).
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance.
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator.
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair).
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders (including but not limited to major depressive disorder or history of suicide attempts).
  • History of relevant orthostatic hypotension, fainting spells, or blackouts. Further exclusion criteria apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    R/T1/T2

    Three period crossover with treatments in the following order: Reference (R): three 6 milligram BI 1015550 film-coated tablets of Trial Formulation 2 (TF2) taken orally following an overnight fast of at least 10 hours. Test treatment 1 (T1): one 18 milligram BI 1015550 film-coated tablet of the intended commercial formulation (iCF) taken orally following an overnight fast of at least 10 hours. Test treatment 2 (T2): one 18 milligram BI 1015550 film-coated tablet of the intended commercial formulation (iCF) taken orally following a high-calorie breakfast. Periods were separated by a washout period of at least 7 days between treatments.

    Drug: Reference (R) · Drug: Test treatment 1 (T1) · Drug: Test treatment 2 (T2)

  • Experimental
    T1/T2/R

    Three period crossover with treatments in the following order: Test treatment 1 (T1): one 18 milligram BI 1015550 film-coated tablet of the intended commercial formulation (iCF) taken orally following an overnight fast of at least 10 hours. Test treatment 2 (T2): one 18 milligram BI 1015550 film-coated tablet of the intended commercial formulation (iCF) taken orally following a high-calorie breakfast. Reference (R): three 6 milligram BI 1015550 film-coated tablets of Trial Formulation 2 (TF2) taken orally following an overnight fast of at least 10 hours. Periods were separated by a washout period of at least 7 days between treatments.

    Drug: Reference (R) · Drug: Test treatment 1 (T1) · Drug: Test treatment 2 (T2)

  • Experimental
    T2/R/T1

    Three period crossover with treatments in the following order: Test treatment 2 (T2): one 18 milligram BI 1015550 film-coated tablet of the intended commercial formulation (iCF) taken orally following a high-calorie breakfast. Reference (R): three 6 milligram BI 1015550 film-coated tablets of Trial Formulation 2 (TF2) taken orally following an overnight fast of at least 10 hours. Test treatment 1 (T1): one 18 milligram BI 1015550 film-coated tablet of the intended commercial formulation (iCF) taken orally following an overnight fast of at least 10 hours. Periods were separated by a washout period of at least 7 days between treatments

    Drug: Reference (R) · Drug: Test treatment 1 (T1) · Drug: Test treatment 2 (T2)

Interventions

  • Reference (R): three 6 milligram BI 1015550 film-coated tablets of Trial Formulation 2 (TF2) taken orally following an overnight fast of at least 10 hours.

    Also known as: Nerandomilast, JASCAYD®

  • Test treatment 1 (T1): one 18 milligram BI 1015550 film-coated tablet of the intended commercial formulation (iCF) taken orally following an overnight fast of at least 10 hours.

    Also known as: Nerandomilast, JASCAYD®

  • Test treatment 2 (T2): one 18 milligram BI 1015550 film-coated tablet of the intended commercial formulation (iCF) taken orally following a high-calorie breakfast.

    Also known as: Nerandomilast, JASCAYD®

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).

    Time frame: Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours following drug administration.

  2. Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of R-BI 1015550 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). The endpoint was analyzed additionally for the chirally pure (R) form of BI 1015550 (R-BI 1015550, the pharmacologically active form).

    Time frame: Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours following drug administration.

  3. Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)

    Maximum measured concentration of BI 1015550 in plasma (Cmax).

    Time frame: Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours following drug administration.

  4. Maximum Measured Concentration of R-BI 1015550 in Plasma (Cmax)

    Maximum measured concentration of R-BI 1015550 in plasma (Cmax). The endpoint was analyzed additionally for the chirally pure (R) form of BI 1015550 (R-BI 1015550, the pharmacologically active form).

    Time frame: Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours following drug administration.

Secondary outcomes

  1. Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Predicted (AUC0-∞,Pred)

    Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity, predicted (AUC0-∞,pred).

    Time frame: Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours following drug administration.

  2. Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Predicted (AUC0-∞,Pred)

    Area under the concentration-time curve of R-BI 1015550 in plasma over the time interval from 0 extrapolated to infinity, predicted (AUC0-∞,pred). The endpoint was analyzed additionally for the chirally pure (R) form of BI 1015550 (R-BI 1015550, the pharmacologically active form).

    Time frame: Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours following drug administration.

07

Results

Posted Dec 19, 2025

Participant flow

The trial was a randomised, open-label, single-dose, three-way crossover design. The subjects were randomly allocated to 1 of 3 treatment sequences. Each subject participated in 3 treatment periods, receiving a single dose in each, with a washout period of at least 7 days between treatments.

Period 1
Participant flow — Period 1
MilestoneR/T1/T2T1/T2/RT2/R/T1
Started888
Completed888
Not completed000
Period 1 - 2 washout
Participant flow — Period 1 - 2 washout
MilestoneR/T1/T2T1/T2/RT2/R/T1
Started888
Completed788
Not completed100
Withdrew: Adverse event100
Period 2
Participant flow — Period 2
MilestoneR/T1/T2T1/T2/RT2/R/T1
Started788
Completed788
Not completed000
Period 2 - 3 washout
Participant flow — Period 2 - 3 washout
MilestoneR/T1/T2T1/T2/RT2/R/T1
Started788
Completed788
Not completed000
Period 3
Participant flow — Period 3
MilestoneR/T1/T2T1/T2/RT2/R/T1
Started788
Completed788
Not completed000

Outcome measures

PrimaryArea Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).

Time frame:
Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours following drug administration.
Reported as:
Geometric mean · hours*nanomol/Liter
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hours*nanomol/LiterReference treatment (R) - fastedTest treatment 1 (T1) - fastedTest treatment 2 (T2) - fed
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)2290 ± 1942740 ± 34.73000 ± 31.2
Statistical analysis
  • Reference treatment (R) - fasted vs Test treatment 1 (T1) - fasted · Gmean ratio: 121.12 · 90% CI 86.14 to 170.30gMean ratio: T1/R. Intra-individual Geometric coefficient of variation \[%\] = 78.5.
  • Test treatment 1 (T1) - fasted vs Test treatment 2 (T2) - fed · Gmean ratio: 108.13 · 90% CI 76.68 to 152.48gMean ratio: T2/T1. Intra-individual Geometric coefficient of variation \[%\] = 78.5.
PrimaryArea Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of R-BI 1015550 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). The endpoint was analyzed additionally for the chirally pure (R) form of BI 1015550 (R-BI 1015550, the pharmacologically active form).

Time frame:
Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours following drug administration.
Reported as:
Geometric mean · hours*nanomol/Liter
Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hours*nanomol/LiterReference treatment (R) - fastedTest treatment 1 (T1) - fastedTest treatment 2 (T2) - fed
Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)1900 ± 1972310 ± 29.62500 ± 26.9
Statistical analysis
  • Reference treatment (R) - fasted vs Test treatment 1 (T1) - fasted · Gmean ratio: 122.01 · 90% CI 79.25 to 187.84gMean ratio: T1/R. Intra-individual Geometric coefficient of variation \[%\] = 104.0.
  • Test treatment 1 (T1) - fasted vs Test treatment 2 (T2) - fed · Gmean ratio: 108.56 · 90% CI 104.33 to 112.97gMean ratio: T2/T1. Intra-individual Geometric coefficient of variation \[%\] = 7.8.
PrimaryMaximum Measured Concentration of BI 1015550 in Plasma (Cmax)

Maximum measured concentration of BI 1015550 in plasma (Cmax).

Time frame:
Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours following drug administration.
Reported as:
Geometric mean · nanomol/Liter
Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)
nanomol/LiterReference treatment (R) - fastedTest treatment 1 (T1) - fastedTest treatment 2 (T2) - fed
Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)313 ± 165364 ± 36.6323 ± 22.7
Statistical analysis
  • Reference treatment (R) - fasted vs Test treatment 1 (T1) - fasted · Gmean ratio: 118.00 · 90% CI 85.82 to 162.25gMean ratio: T1/R. Intra-individual Geometric coefficient of variation \[%\] = 72.2.
  • Test treatment 1 (T1) - fasted vs Test treatment 2 (T2) - fed · Gmean ratio: 87.94 · 90% CI 63.77 to 121.28gMean ratio: T2/T1. Intra-individual Geometric coefficient of variation \[%\] = 72.2.
PrimaryMaximum Measured Concentration of R-BI 1015550 in Plasma (Cmax)

Maximum measured concentration of R-BI 1015550 in plasma (Cmax). The endpoint was analyzed additionally for the chirally pure (R) form of BI 1015550 (R-BI 1015550, the pharmacologically active form).

Time frame:
Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours following drug administration.
Reported as:
Geometric mean · nanomol/Liter
Maximum Measured Concentration of R-BI 1015550 in Plasma (Cmax)
nanomol/LiterReference treatment (R) - fastedTest treatment 1 (T1) - fastedTest treatment 2 (T2) - fed
Maximum Measured Concentration of R-BI 1015550 in Plasma (Cmax)307 ± 166352 ± 35.4319 ± 23.8
Statistical analysis
  • Reference treatment (R) - fasted vs Test treatment 1 (T1) - fasted · Gmean ratio: 115.63 · 90% CI 77.64 to 172.22gMean ratio: T1/R. Intra-individual Geometric coefficient of variation \[%\] = 93.3.
  • Test treatment 1 (T1) - fasted vs Test treatment 2 (T2) - fed · Gmean ratio: 90.74 · 90% CI 80.82 to 101.87gMean ratio: T2/T1. Intra-individual Geometric coefficient of variation \[%\] = 23.0.
SecondaryArea Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Predicted (AUC0-∞,Pred)

Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity, predicted (AUC0-∞,pred).

Time frame:
Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours following drug administration.
Reported as:
Geometric mean · hours*nanomol/Liter
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Predicted (AUC0-∞,Pred)
hours*nanomol/LiterReference treatment (R) - fastedTest treatment 1 (T1) - fastedTest treatment 2 (T2) - fed
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Predicted (AUC0-∞,Pred)2970 ± 30.02780 ± 35.13050 ± 31.7
Statistical analysis
  • Reference treatment (R) - fasted vs Test treatment 1 (T1) - fasted · Gmean ratio: 93.79 · 90% CI 90.49 to 97.21gMean ratio: T1/R. Intra-individual Geometric coefficient of variation \[%\] = 7.1.
  • Test treatment 1 (T1) - fasted vs Test treatment 2 (T2) - fed · Gmean ratio: 109.51 · 90% CI 105.72 to 113.44gMean ratio: T2/T1. Intra-individual Geometric coefficient of variation \[%\] = 7.1.
SecondaryArea Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Predicted (AUC0-∞,Pred)

Area under the concentration-time curve of R-BI 1015550 in plasma over the time interval from 0 extrapolated to infinity, predicted (AUC0-∞,pred). The endpoint was analyzed additionally for the chirally pure (R) form of BI 1015550 (R-BI 1015550, the pharmacologically active form).

Time frame:
Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours following drug administration.
Reported as:
Geometric mean · hours*nanomol/Liter
Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Predicted (AUC0-∞,Pred)
hours*nanomol/LiterReference treatment (R) - fastedTest treatment 1 (T1) - fastedTest treatment 2 (T2) - fed
Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Predicted (AUC0-∞,Pred)2460 ± 27.02340 ± 30.02530 ± 27.2
Statistical analysis
  • Reference treatment (R) - fasted vs Test treatment 1 (T1) - fasted · Gmean ratio: 95.01 · 90% CI 91.39 to 98.77gMean ratio: T1/R. Intra-individual Geometric coefficient of variation \[%\] = 7.5.
  • Test treatment 1 (T1) - fasted vs Test treatment 2 (T2) - fed · Gmean ratio: 108.30 · 90% CI 103.90 to 112.89gMean ratio: T2/T1. Intra-individual Geometric coefficient of variation \[%\] = 8.2.

Adverse events

Collected over Adverse events: From trial medication intake till the end of the residual effect period (REP), up to 7 days. All-Cause Mortality: Up to 14 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reference Treatment (R) - Fasted0/24 (0%)0/24 (0%)5/24 (20.8%)
Test Treatment 1 (T1) - Fasted0/23 (0%)0/23 (0%)3/23 (13%)
Test Treatment 2 (T2) - Fed0/23 (0%)0/23 (0%)2/23 (8.7%)
Most frequent other events
Most frequent other events
EventReference Treatment (R) - FastedTest Treatment 1 (T1) - FastedTest Treatment 2 (T2) - Fed
HeadacheNervous system disorders5/243/232/23

Baseline characteristics

Treated set (TS): The treated set included all subjects who were treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(years)R/T1/T2T1/T2/RT2/R/T1Total
Mean38.5 ± 11.340.0 ± 11.839.6 ± 14.239.4 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)R/T1/T2T1/T2/RT2/R/T1Total
Female5139
Male37515
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)R/T1/T2T1/T2/RT2/R/T1Total
Hispanic or Latino0011
Not Hispanic or Latino88723
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)R/T1/T2T1/T2/RT2/R/T1Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White88824
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Sep 2022, 1 month.

Results were first posted in Dec 2025, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2022
First posted
Jun 23, 2022
StartActual
Aug 15, 2022
Primary completionActual
Sep 30, 2022
CompletionActual
Sep 30, 2022
Results first posted
Dec 19, 2025
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05428436
Responsible party
Sponsor
First posted
Jun 23, 2022
Start date
Aug 15, 2022
Primary completion
Sep 30, 2022
Completion
Sep 30, 2022
Results posted
Dec 19, 2025
Last update
Dec 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion